Moderna and Cenra Healthcare Enter Joint Agreement to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Taiwan, Including COVID-19 Vaccines
Moderna and Cenra Healthcare have announced a joint agreement for the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Taiwan, including the COVID-19 vaccine Spikevax. The agreement, effective until July 31, 2027, involves Moderna manufacturing and distributing the vaccines, while Cenra Healthcare will handle promotion and medical education activities to ensure broad access across Taiwan.
Joyce Lee, General Manager of Moderna in Taiwan, expressed excitement about partnering with Cenra Healthcare, citing their expertise in infectious diseases and respiratory products. Lucas Lin, General Manager of Cenra Healthcare, emphasized their ability to support Taiwan's immunization programs through collaboration with healthcare providers and communities.
The partnership aims to advance public health initiatives in Taiwan, particularly as respiratory diseases continue to pose a global threat. Financial terms of the deal were not disclosed.
Moderna e Cenra Healthcare hanno annunciato un accordo congiunto per la co-promozione del portafoglio di vaccini respiratori mRNA di Moderna a Taiwan, incluso il vaccino COVID-19 Spikevax. L'accordo, valido fino al 31 luglio 2027, prevede che Moderna si occupi della produzione e distribuzione dei vaccini, mentre Cenra Healthcare gestirà le attività di promozione e formazione medica per garantire un ampio accesso in tutto il Taiwan.
Joyce Lee, Direttore Generale di Moderna a Taiwan, ha espresso entusiasmo per la collaborazione con Cenra Healthcare, sottolineando la loro esperienza nelle malattie infettive e nei prodotti respiratori. Lucas Lin, Direttore Generale di Cenra Healthcare, ha messo in evidenza la loro capacità di supportare i programmi di immunizzazione a Taiwan attraverso la collaborazione con fornitori di assistenza sanitaria e comunità.
Il partenariato mira a promuovere iniziative di salute pubblica a Taiwan, in particolare poiché le malattie respiratorie continuano a rappresentare una minaccia globale. I termini finanziari dell'accordo non sono stati resi noti.
Moderna y Cenra Healthcare han anunciado un acuerdo conjunto para la co-promoción del portafolio de vacunas respiratorias mRNA de Moderna en Taiwán, incluyendo la vacuna COVID-19 Spikevax. El acuerdo, efectivo hasta el 31 de julio de 2027, implica que Moderna fabricará y distribuirá las vacunas, mientras que Cenra Healthcare se encargará de las actividades de promoción y educación médica para asegurar un amplio acceso en toda Taiwán.
Joyce Lee, Gerente General de Moderna en Taiwán, expresó su entusiasmo por asociarse con Cenra Healthcare, citando su experiencia en enfermedades infecciosas y productos respiratorios. Lucas Lin, Gerente General de Cenra Healthcare, enfatizó su capacidad para apoyar los programas de inmunización de Taiwán a través de la colaboración con proveedores de atención médica y comunidades.
La asociación tiene como objetivo promover iniciativas de salud pública en Taiwán, especialmente dado que las enfermedades respiratorias continúan representando una amenaza global. No se revelaron los términos financieros del acuerdo.
모더나와 센라 헬스케어는 대만에서 모더나의 mRNA 호흡기 백신 포트폴리오를 공동 프로모션하기 위한 공동 계약을 발표했습니다. 여기에는 COVID-19 백신 Spikevax이 포함됩니다. 이 계약은 2027년 7월 31일까지 유효하며, 모더나는 백신의 제조 및 배포를 담당하고 센라 헬스케어는 대만 전역에서의 폭넓은 접근을 보장하기 위해 홍보 및 의료 교육 활동을 실시합니다.
대만 모더나의 조이스 리 총괄 매니저는 감염병 및 호흡기 제품에 대한 전문성을 언급하며 센라 헬스케어와 협력하게 되어 기쁘다고 밝혔습니다. 센라 헬스케어의 루카스 린 총괄 매니저는 의료 제공자 및 커뮤니티와의 협력을 통해 대만의 면역 프로그램을 지원할 수 있는 능력을 강조했습니다.
이번 파트너십은 대만에서의 공공 보건 이니셔티브를 발전시키는 것을 목표로 하며, 호흡기 질환이 글로벌 위협으로 지속되고 있는 상황에서 더욱 중요합니다. 계약의 재정 조건은 공개되지 않았습니다.
Moderna et Cenra Healthcare ont annoncé un accord commun pour la co-promotion du portefeuille de vaccins respiratoires à ARNm de Moderna à Taiwan, y compris le vaccin COVID-19 Spikevax. L'accord, valide jusqu'au 31 juillet 2027, implique que Moderna fabriquera et distribuera les vaccins, tandis que Cenra Healthcare se chargera des activités de promotion et de formation médicale afin d'assurer un large accès à travers Taiwan.
Joyce Lee, Directrice Générale de Moderna à Taiwan, a exprimé son enthousiasme à l'idée de s'associer à Cenra Healthcare, soulignant leur expertise dans les maladies infectieuses et les produits respiratoires. Lucas Lin, Directeur Général de Cenra Healthcare, a mis l'accent sur leur capacité à soutenir les programmes d'immunisation de Taiwan par la collaboration avec les prestataires de soins de santé et les communautés.
Le partenariat vise à faire avancer les initiatives de santé publique à Taiwan, en particulier alors que les maladies respiratoires continuent de représenter une menace mondiale. Les conditions financières de l'accord n'ont pas été divulguées.
Moderna und Cenra Healthcare haben eine gemeinsame Vereinbarung zur Co-Promotion des mRNA-Atmungsimpfstoff-Portfolios von Moderna in Taiwan angekündigt, einschließlich des COVID-19-Impfstoffs Spikevax. Die Vereinbarung, die bis zum 31. Juli 2027 gültig ist, sieht vor, dass Moderna die Impfstoffe produziert und vertreibt, während Cenra Healthcare die Promotion und medizinischen Bildungsaktivitäten übernimmt, um einen breiten Zugang in ganz Taiwan zu gewährleisten.
Joyce Lee, General Manager von Moderna in Taiwan, äußerte sich begeistert über die Partnerschaft mit Cenra Healthcare und hob deren Expertise in Infektionskrankheiten und respiratorischen Produkten hervor. Lucas Lin, General Manager von Cenra Healthcare, betonte die Fähigkeit ihrerseits, Taiwans Immunisierungsprogramme durch Zusammenarbeit mit Gesundheitsdienstleistern und Gemeinden zu unterstützen.
Die Partnerschaft zielt darauf ab, Initiativen zur öffentlichen Gesundheit in Taiwan voranzutreiben, insbesondere angesichts der anhaltenden globalen Bedrohung durch Atemwegserkrankungen. Die finanziellen Bedingungen des Vertrags wurden nicht bekannt gegeben.
- Expanded market access for Moderna's mRNA vaccines in Taiwan
- Partnership with a trusted local leader in Taiwan's medical industry
- Potential for increased vaccine distribution and sales in the Taiwanese market
- Enhanced promotional and educational efforts for Moderna's vaccine portfolio
- None.
Insights
This partnership between Moderna and Cenra Healthcare represents a strategic move to expand Moderna's presence in the Taiwanese market. The agreement focuses on co-promoting Moderna's mRNA respiratory vaccine portfolio, including the COVID-19 vaccine Spikevax®. This collaboration leverages Cenra's strong local presence and expertise in infectious diseases to potentially increase Moderna's market share in Taiwan.
Key points to consider:
- The initial term until July 31, 2027, provides a substantial timeframe for market penetration and growth.
- While financial terms are undisclosed, this deal could lead to increased revenue streams for Moderna in the Asia-Pacific region.
- The partnership may help Moderna navigate local regulatory landscapes and healthcare systems more effectively.
- This move aligns with Moderna's global strategy to expand its vaccine distribution and could serve as a model for similar agreements in other markets.
For investors, this partnership signals Moderna's commitment to global expansion and diversification of its revenue sources beyond its home market. However, the impact on Moderna's bottom line remains to be seen, given the lack of financial details provided.
This agreement marks a significant step for Moderna in expanding its global footprint, particularly in the Asian market. Taiwan, with its population of approximately 23 million and advanced healthcare system, presents a valuable opportunity for Moderna to increase its vaccine distribution.
Key market implications:
- Potential for increased market share in Taiwan's vaccine sector, which could translate to higher revenues for Moderna.
- Enhanced brand recognition in the Asia-Pacific region, potentially leading to further partnerships or market expansions.
- Diversification of Moderna's revenue streams, reducing dependence on a single market.
- Possible positive impact on Moderna's stock price if the partnership yields significant results.
Investors should monitor the success of this partnership as it could serve as an indicator of Moderna's ability to penetrate new markets effectively. The long-term nature of the agreement (until 2027) provides stability and allows time for the partnership to yield measurable results. However, the lack of financial details makes it challenging to quantify the immediate impact on Moderna's valuation.
CAMBRIDGE, MA and TAIPEI, TAIWAN / ACCESSWIRE / September 30, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Cenra Healthcare, the sales and marketing arm of Cenra Inc., today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Taiwan, including Moderna's COVID-19 vaccine, Spikevax®.
Under the agreement, Moderna will manufacture and distribute its mRNA respiratory vaccines. Cenra Healthcare will engage in promotion and execute medical education activities to ensure broad access to Moderna's mRNA respiratory portfolio across Taiwan. The agreement has an initial term until July 31, 2027, and no further details on the financial terms of the deal are being disclosed.
"We are excited to partner with Cenra Healthcare, a trusted leader in Taiwan's medical industry with extensive expertise in infectious diseases and respiratory products," said Joyce Lee, General Manager of Moderna in Taiwan. "Their strong presence in the market will help ensure broader access to our vaccines. We are committed to advancing public health initiatives across Taiwan, and this partnership will enable us to expand our educational efforts around our COVID-19 vaccine and future portfolio, especially as respiratory diseases continue to pose a global threat."
"At Cenra, we are proud and excited to partner with a global innovator like Moderna to contribute to Taiwan's public health efforts," said Lucas Lin, General Manager, Cenra Healthcare. "With our leading market presence and deep understanding of Taiwan's healthcare landscape, along with Moderna's world-class mRNA vaccines, Cenra Healthcare is well-equipped to support Taiwan's immunization programs by ensuring access through seamless collaboration with healthcare providers and communities."
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
About Cenra Healthcare
Cenra Healthcare, established in 2004 as the sales and marketing arm of Cenra Inc., is a leader in providing comprehensive healthcare solutions tailored to meet the diverse needs of individuals in Taiwan and beyond. Cenra Healthcare specializes in the distribution of high-quality pharmaceuticals and innovative healthcare products, ensuring accessibility and affordability for all.
Founded in 1952, Cenra Inc. is one of the leading healthcare companies in Taiwan, with its subsidiaries and affiliates covering a wide range of areas, including human and veterinary pharmaceuticals, active pharmaceutical ingredients, health supplements, over-the-counter (OTC) drug products, household and beauty products, and elderly care services. Cenra is driven by a vision of "Empowering health equity, propelling a healthier world for all," and is committed to delivering impactful health solutions and enhancing public health through partnerships and strategic alliances. For more information, please visit cenra.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna and Cenra Healthcare's joint agreement to co-promote Moderna's mRNA respiratory vaccine portfolio in Taiwan; and the companies' ability to ensure broad access to Moderna's mRNA respiratory portfolio across Taiwan. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.
Moderna Contacts
Media:
Luke Mircea-Willats
Senior Director, International Communications
Luke.mirceawillats@modernatx.com
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com
Cenra Contacts
Media:
Tiffany Chen
Director, Corporate Affairs & Communications
Tiffany.chen@cenra.com
SOURCE: Moderna, Inc.
View the original press release on accesswire.com
FAQ
What is the purpose of Moderna's partnership with Cenra Healthcare in Taiwan?
How long is the agreement between Moderna (MRNA) and Cenra Healthcare valid?
What are the roles of Moderna (MRNA) and Cenra Healthcare in this partnership?
Will this partnership affect Moderna's (MRNA) COVID-19 vaccine distribution in Taiwan?
